brentuximab

1-14 of 14 Search Results for

Sort by

Sort Order Select

Book Chapter

Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab

Book: Adverse Reactions to Biologics

Series: Current Problems in Dermatology

Volume: 53

Published: 13 November 2017

10.1159/000478079

EISBN: 978-3-318-06101-7

... on the safety profile of mAbs therapies that have recently been approved or are currently under preclinical or clinical investigation for CBCLs (rituximab) and CTCLs (brentuximab, mogamulizumab, and alemtuzumab). Further studies to define clinical safety profile in the patient cohort with cutaneous lymphomas...

Open the PDF for Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab in another window

Book Chapter

References

Book: Adverse Reactions to Biologics

Series: Current Problems in Dermatology

Volume: 53

Published: 13 November 2017

EISBN: 978-3-318-06101-7

.... Arthritis Rheum 2009;60:3225-3228. 33. Al-Tawfiq JA, Banda RW, Daabil RA, Dawamneh MF: Progressive multifocal leukoencephalopathy (PML) in a patient with lymphoma treated with rituximab: a case report and literature review. J Infect Public Health 2015;8:493-497. 34. Brentuximab vedotin. Federal...

Book

Adverse Reactions to Biologics

Series: Current Problems in Dermatology

Volume: 53

Published: 13 November 2017

10.1159/isbn.978-3-318-06101-7

EISBN: 978-3-318-06101-7

Book

Fast Facts: Peripheral T-cell Lymphoma: Unraveling the complexities of diagnosis and management

Published: 20 June 2019

10.1159/isbn.978-1-912776-19-1

EISBN: 978-1-912776-19-1

Open the PDF for Fast Facts: Peripheral T-cell Lymphoma: Unraveling the complexities of diagnosis and management in another window

Book Chapter

References

Book: Tumors in Adolescents and Young Adults

Series: Progress in Tumor Research

Volume: 43

Published: 08 September 2016

EISBN: 978-3-318-05912-0

... event-free survival in patients with Hodgkin lymphoma. Blood 2012;119:1665-1670. 67. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821. 68. Moskowitz CH, Nademanee A, Masszi T, et al: Brentuximab vedotin...

Book Chapter

Lymphoma in Adolescents and Young Adults

Book: Tumors in Adolescents and Young Adults

Series: Progress in Tumor Research

Volume: 43

Published: 08 September 2016

10.1159/000447080

EISBN: 978-3-318-05912-0

... rates of 74 and 92.5%, respectively [ 43 ] whereas adult patients are generally treated according to protocols designed for DLBCL mostly with anthracycline-containing regimens (CHOP, CHOEP (CHOP + etoposide)) [ 41 ]. Several promising targeted agents such as CD30 immunoconjugate brentuximab vedotin...

Open the PDF for Lymphoma in Adolescents and Young Adults in another window

Book

Fast Facts: Cutaneous T-cell Lymphoma

Published: 25 April 2019

10.1159/isbn.978-1-912776-31-3

EISBN: 978-1-912776-31-3

Open the PDF for Fast Facts: Cutaneous T-cell Lymphoma in another window

Book

Fast Facts: Lymphoma

Published: 16 October 2018

10.1159/isbn.978-1-910797-95-2

EISBN: 978-1-910797-95-2

Open the PDF for Fast Facts: Lymphoma in another window

Book Chapter

Increasing Access to Clinical Trials and Innovative Therapy for Teenagers and Young Adults with Cancer - A Multiple Stakeholders and Multiple Steps Process

Book: Tumors in Adolescents and Young Adults

Series: Progress in Tumor Research

Volume: 43

Published: 08 September 2016

10.1159/000447043

EISBN: 978-3-318-05912-0

...-threatening advanced malignancies, by limiting or delaying adolescent access to new promising drugs, such as brentuximab in Hodgkin lymphoma, vemurafenib and anti-PD1 antibodies in melanoma. In addition, access to these early studies would ultimately increase our better knowledge of TYA tumor biology...